The Australian National Bowel Cancer Screening Program (NBCSP) will fully roll-out 2-yearly screening using the immunochemical Faecal Occult Blood Testing (iFOBT) in people aged 50 to 74 years by 2020. In this study, we aimed to estimate the comparative health benefits, harms, and cost-effectiveness of screening with iFOBT, versus other potential alternative or adjunctive technologies. A comprehensive validated microsimulation model, Policy1-Bowel, was used to simulate a total of 13 screening approaches involving use of iFOBT, colonoscopy, sigmoidoscopy, computed tomographic colonography (CTC), faecal DNA (fDNA) and plasma DNA (pDNA), in people aged 50 to 74 years. All strategies were evaluated in three scenarios: (i) perfect adherence, (ii) high (but imperfect) adherence, and (iii) low adherence. When assuming perfect adherence, the most
effective strategies involved using iFOBT (annually, or biennially with/without adjunct sigmoidoscopy either at 50, or at 54, 64 and 74 years for individuals with negative iFOBT), or colonoscopy (10-yearly, or once-off at 50 years combined with biennial iFOBT). Colorectal cancer incidence (mortality) reductions for these strategies were 51-67(74-80)% in comparison with no screening; 2-yearly iFOBT screening (i.e. the NBCSP) would be associated with reductions of 51(74)%. Only 2-yearly iFOBT screening was found to be cost-effective in all scenarios in context of an indicative willingness-to-pay threshold of A$50,000/ life-year saved (LYS); this strategy was associated with an incremental cost-effectiveness ratio of A$2,984/LYS-A$5,981/LYS (depending on adherence). The fully rolled-out NBCSP is highly cost-effective, and is also one of the most effective approaches for bowel cancer screening in Australia.
Trials and observational studies have shown that colorectal cancer mortality can be reduced by screening with guaiac Faecal Occult Blood Testing (gFOBT) (by 13-33%), [1] [2] [3] flexible sigmoidoscopy (FS) (by 21-31%) [4] [5] [6] [7] [8] and colonoscopy (by 68-88%). 5, 9, 10 Potential alternative screening technologies, such as computed tomographic colonography (CTC), plasma DNA testing (pDNA) and multitarget faecal DNA testing (fDNA) have also been assessed for the detection of adenomas and cancer in the colorectum. [11] [12] [13] [14] Therefore, a number of approaches to population screening could potentially be taken, but their population-level effects in Australia have not been assessed.
In Australia, the National Bowel Cancer Screening Program (NBCSP) will complete full roll-out by 2020, and will offer free 2-yearly immunochemical Faecal Occult Blood Testing (iFOBT) screening for people aged 50-74 years. 15 We have previously reported that with current levels of participation (37% of individuals invited to participate in the NBCSP in 2013-2014), 16 the NBCSP is expected to prevent 92,200 cancer cases and 59,000 deaths over the 25-year period from 2015 to 2040, with an additional 24,300 and 37,300 cases and 16,800 and 24,800 deaths prevented if participation was increased to 50% and 60%, respectively. 17 We also found that the program is highly cost-effective due to the cancer treatment costs averted [cost-effectiveness ratio compared to no screening, A$2,000/life-year saved (LYS)-A$3,000/LYS]. However, in previous work we did not compare the fully rolled-out NBCSP to other potential alternative screening approaches. A recent evaluation conducted by the US Preventive Services Task Force (USPSTF) compares eight different colorectal cancer screening approaches involving high-sensitivity gFOBT (HSgFOBT), iFOBT, fDNA, CTC, colonoscopy, sigmoidoscopy, or sigmoidoscopy combined with either HSgFOBT or iFOBT. 18 Under the assumption of 100% screening adherence, and using estimated lifeyears and the number of colonoscopies of each screening strategy, the USPSTF study found that screening with 10-yearly colonoscopy, 10-yearly sigmoidoscopy combined with annual iFOBT, 5-yearly CTC, and annual iFOBT at ages 50 to 75 years would provide the best balance of benefits to harms in the U.S. context. However, the study did not report on the impact of more realistic compliance assumptions (which could be expected to differ by screening modality and frequency) on either benefits or harms. Furthermore, cost-effectiveness was not considered because this is not part of the domain of issues considered by the USPSTF. The USPSTF provides information about the extent to what recommendations are supported by evidence, but with the understanding that policy-makers and clinicians will need to consider other factors, including cost-effectiveness. 19 The comparative benefits, harms, and cost-effectiveness of the NBSCP compared to other potential alternative or adjunctive options for screening in Australia have not yet been evaluated. The aim of this study was therefore to evaluate the health benefits, harms, and cost-effectiveness of colorectal cancer screening with iFOBT, versus screening approaches using colonoscopy, sigmoidoscopy, CTC, fDNA and pDNA. This evaluation was performed to support the 2017 review of the Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer, which was auspiced by Cancer Council Australia.
Material and Methods

Policy1-Bowel model platform
A comprehensive microsimulation model, Policy1-Bowel, was used for the evaluation. The model simulates both the adenoma-carcinoma pathway and the serrated pathway in colorectal cancer development, assuming 15% of colorectal cancers are attributable to the serrated pathway. It was adapted from an existing colorectal cancer natural history model, the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) model 20 and was extensively re-calibrated jointly to the original natural history data 21 and the Australian setting. 17 Detailed calibration and validation results for the Australian implementation have been described elsewhere. 17 Briefly, the Policy1-Bowel model is constructed using Microsoft Visual Studio 2013 C11. The simulation begins from age 20 and continues on an annual time-step until the virtual individual dies or becomes 90 years old, whichever occurs first. The age-and sex-specific probability of dying from causes other than colorectal cancer was derived by subtracting the colorectal cancer mortality rate 22 from the allcause mortality rate 23 in Australia in 2011. Although the model has undergone extensive calibration and validation, most of the observed data on adenoma used for calibration were available only up to age 74 years. 17 Routinely reported data in Australia groups all people aged 85 or older. 24 Furthermore, the age expectancy at the age of 90 years is <5 years for Australian men and women, 25 implying a high competing risk of death from causes other than bowel cancer. Therefore, in the base case analysis we terminated the simulation at the age of 90 years. In the analysis of screening, the oldest age of screening for the modelled screening strategies was 75 years; therefore, stopping the simulation at 90 years allows a further 15 years in which to capture the majority of the remaining lifetime effects (health and costs) associated with screening. In the current analysis, lifetime outcomes for a single age cohort consisting of 20 million males and 20 million females were simulated for each strategy evaluated. In addition to the probability of dying from other noncolorectal-cancer-related causes, colorectal cancer patients in the model were assumed to have a probability of dying from cancer for a period limited to five years from diagnosis. The modelled cancer survival probabilities vary by cancer stage, time since cancer diagnosis and whether the cancer was diagnosed due to symptomatic detection or via screening. The modelled 5-year survival of symptomatically detected colorectal cancer patients was calibrated to data from Western Australia as previously described. 17, 26 Screen-detected colorectal cancer patients were assumed to have improved survival compared with patients whose cancer was symptomatically diagnosed at the same stage, consistent with data from international studies. [27] [28] [29] Colorectal patients who survived for 5 years after detection and treatment of cancer were considered cancer survivors in the model. These survivors are assumed to have no additional risk of dying from colorectal cancer compared with the average population with no colorectal cancer. See Supporting Information Appendix for more information on the modelled cancer survival assumptions.
Screening and follow-up management strategies, test characteristics and cost assumptions A total of 13 strategies using various test technologies for bowel screening, including iFOBT, colonoscopy, sigmoidoscopy, CTC, pDNA and fDNA, alone and in combination, and at different screening intervals were evaluated ( Table 1) . The screening strategies of interest were determined in a series of consultations with the population screening subcommittee of the Working Party for the review of the Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer. Test characteristics and costs were informed by a review of the literature and Australian reimbursement data. Analyses for fDNA, pDNA and CTC were considered exploratory since modelling was based on cross-sectional observational data on test characteristics, given no longitudinal data on longer term outcomes were available. A health services perspective was taken in this study. Overhead costs related to administration (other than the costs of sending invitations and test kits, and return of tests) and promotion of the screening program and individual out-of-pocket costs were not included. For the alternate strategies, we assumed that home-based sample collection would not be done, and therefore invitation letters asking participants to visit their general practitioner as a first step in the process would be required. As a result, the costs for modelled screening strategies using technology other than iFOBT all included the costs of sending an initial invitation letter. The assumed costs, test characteristics and data sources for each of the screening approaches are summarised in Table 2 . A detailed description of the modelled test characteristics are provided in the Supporting Information Appendix. Individuals who underwent iFOBT, pDNA or fDNAbased screening were assumed to be referred to colonoscopy for further diagnosis if the screening test outcome was positive; individuals who underwent CTC or sigmoidoscopy screening were referred to colonoscopy if any polyps were detected. Adenomas <5 mm detected during sigmoidoscopy were assumed to be treated via immediate polypectomy; polyps 5 mm were assumed not to be removed during sigmoidoscopy but to be treated in the follow-up colonoscopy. Polypectomy was assumed to be performed on all adenomas detected during colonoscopy. After referral colonoscopy, individuals were returned to the modelled routine screening strategy if no adenomatous polyps were detected (i.e. returned to 10-yearly colonoscopy screening for strategy COL10y, returned to 2-yearly pDNA testing for strategy plasmaDNA2y etc.); or further follow-up with surveillance colonoscopy in 1-5 years if any adenomatous polyps were detected (with further management depending on findings during serial colonoscopy follow-up). Detailed management assumptions for screening, diagnosis and surveillance are provided in the Supporting Information Appendix. We assumed no screening occurred after the recommended screening stopping age specified by each strategy and that colonoscopy surveillance stopped at age 75 years, based on existing guidelines. 47 
Screening participation (adherence) assumptions
Participation assumptions, which took into account technology-specific issues and health services delivery issues for each option, were determined in a series of consultations with the population screening sub-committee of the Working Party. All strategies were evaluated under three screening adherence assumptions-perfect adherence (Scenario 1), high (but imperfect) adherence (Scenario 2), and low adherence (Scenario 3; current observed rate). Scenario 1 assumed a perfect adherence to screening invitation, follow-up colonoscopy referral after an abnormal screening outcome, and surveillance colonoscopy referral after any conventional adenoma/sessile serrated adenoma detected at colonoscopy. For Scenario 2, the screening initiation rate (i.e. screening participation rate among individuals who have never participated in screening) for the first invitation was assumed to be 57% for screening strategies using iFOBT, pDNA and fDNA, and 35% for screening strategies using colonoscopy, sigmoidoscopy and CTC; for Scenario 3 the corresponding participation rates were 29% and 15%. The screening initiation rate for the second invitation was assumed to be half of the strategy-specific rate modelled for first invitation; this assumption was based on the participation rate of Round 2 NBSCP invitation among individuals who did not participate in Round 1 screening. 15 The initiation rate in subsequent rounds were assumed to be half of the rate modelled for the second round invitation. Assuming a lower screening participation rate for strategies using colonoscopy, sigmoidoscopy and CTC as screening tests compared to strategies using iFOBT, pDNA and fDNA testing is consistent with the findings of a systematic review. 48 In both Scenarios 2 and 3, the modelled rescreening probabilities (i.e. screening participation rate among individuals who have been screened at least once before) was 75% (currently observed rate), 49 the modelled compliance to colonoscopy follow-up after an abnormal screening outcome was 71% (currently observed rate), 49 and the compliance to surveillance recommendations was assumed to be 80% (assumption). More information on the screening participation and follow-up compliance assumptions are provided in the Supporting Information Appendix.
Modelled analysis
We simulated the age-specific colorectal cancer incidence, colorectal cancer mortality, cost, life-years and the number of screening and diagnostic tests that occurred over the lifetime of a single cohort for each strategy. The age-standardised rates for colorectal cancer incidence and colorectal cancer mortality of all ages (i.e. 0-100 years, assuming no colorectal cancer in individual aged <20 years) were calculated assuming the 2001 Australian Standard Population. The health benefits associated with each of the strategies were estimated via the relative reduction in cancer incidence and mortality rates compared with no screening, over the lifetime of the cohort from birth. The total discounted lifetime costs and discounted life-years were calculated by accruing the predicted costs and life-years from age 20 to 89 years and discounting at a rate of 5% from age 40 years. 50 Cost-effectiveness ratios (CERs) were calculated for each strategy by dividing the incremental discounted cost by the incremental discounted life-years achieved compared to no screening. Incremental cost-effectiveness ratios (ICERs) were calculated for each dominating strategy (i.e. the strategy with the lowest cost compared to strategies with similar or lower effectiveness) in the cost-effectiveness analysis by dividing the incremental cost by the incremental life-years from the next most effective dominating strategy identified in the cost-effectiveness analysis, using standard methods. There is no direct source document on cost-effectiveness analysis guidelines to inform the choice on the perspective for non-pharmaceutical interventions in Australia. In this study, we have used the same perspective, discount rate and willingness-to-pay (WTP) threshold ($50,000/LYS) as per a predicate Medical Services Advisory Committee (MSAC) evaluation of the National Cervical Screening Program. 51 Resource utilisation was estimated over the lifetime of 100,000 persons alive at 40 years. The number-needed-to-colonoscope (NNC) to prevent one cancer case and cancer death (compared to no screening) was calculated by dividing the number of colonoscopies (including colonoscopies performed for the purpose of screening, follow-up of a positive screening test outcome and surveillance) by the number of cancer cases/deaths estimated over the lifetime of 100,000 persons alive at 40 years for each strategy. An incremental number-needed-to-colonoscope (INNC) was then calculated for each dominating strategy in the benefit-to-harm analysis by dividing the additional number of colonoscopies (ACs) by the additional number of colorectal cancer deaths prevented (CDP) from the next most beneficial dominating strategy in the benefit-to-harm analysis. All costs are presented in 2015 Australian dollars ($A1 5 US$0.7706, 20 June 2015). One-way sensitivity analysis was performed for key parameters to characterise the impact of varying these parameters across a feasible range on the ranking of strategies in the cost-effectiveness analysis. Supplementary analysis was performed to assess the impact of the simulation stop age on the predicted health and costeffectiveness outcomes by repeated simulations for all screening strategies under three different participation scenarios with the simulation stopping at the age of 100.
Results
Colorectal cancer incidence and mortality reductions
When assuming perfect adherence to screening, follow-up and surveillance recommendations (Scenario 1), and considering the range of results for all 13 strategies, colorectal cancer screening was predicted to reduce the overall agestandardised colorectal cancer incidence (all ages) by 35-67% and to reduce colorectal cancer mortality by 40-80% compared with no screening (Table 3 ). The corresponding reductions were 9-47% and 10-68%, respectively, when assuming high (but imperfect) adherence to screening, follow-up and surveillance recommendations (Scenario 2), and 4-38% and 4-56%, respectively, when assuming low adherence (Scenario 3). The 2-yearly iFOBT screening strategy (i.e. the fully rolled-out NBCSP) was predicted to reduce overall colorectal cancer incidence by 51% and mortality by 74% in Scenario 1, 32% and 51%, respectively in Scenario 2, and 23% and 36%, respectively in Scenario 3, compared with no screening. When assuming perfect adherence to screening and follow-up recommendations (Scenario 1), six strategies predicted a reduction in colorectal cancer mortality (compared with no screening) 74%-these were 10-yearly colonoscopy screening (78%), once-off colonoscopy at 50 years combined with 2-yearly iFOBT screening (78%), annual iFOBT screening (80%), 2-yearly iFOBT screening (74%), and 2-yearly iFOBT screening with adjunctive sigmoidoscopy either at 50 years or 54, 64, and 74 years for individuals with negative iFOBT results (77-80%) ( Table 3) . After accounting for more realistic compliance to screening, follow-up and surveillance recommendations (Scenarios 2 and 3), the six most effective strategies predicted a 51% reduction in colorectal cancer mortality in Scenario 2 and 36% in Scenario 3: these were once-off colonoscopy screening at 50 years combined with 2-yearly iFOBT screening (Scenario 2: 55%; Scenario 3: 39%), annual iFOBT (Scenario 2: 68%; Scenario 3: 56%), 2-yearly iFOBT (Scenario 2: 51%; Scenario 3: 36%), 2-yearly iFOBT screening with adjunct sigmoidoscopy either at 50 years or 54, 64, and 74 years screening for individuals with negative iFOBT (Scenario 2: 52-55%; Scenario 3: 37-38%), and 2-yearly iFOBT combined with pDNA testing for underscreened individuals, assuming that the offer of pDNA does not induce any "leakage" (participation drop) in iFOBT screening (Scenario 2: 52%; Scenario 3: 39%) ( Table 3) . Screening with 10-yearly colonoscopy was predicted to be one of most effective strategies when assuming perfect adherence (Scenario 1) but not when more realistic compliance was assumed (Scenarios 2 and 3) ( Table 3) . Screening with once-off sigmoidoscopy at 60 years was predicted to be the least effective strategy with the lowest reductions in colorectal cancer incidence (Scenario 1: 35%, Scenario 2: 9%; Scenario 3: 4%) and mortality (Scenario 1: 40%, Scenario 2: 10%; Scenario 3: 4%) compared to other strategies included in this evaluation.
Cost-effectiveness
The estimated life-years, lifetime cost and the costeffectiveness ratio compared to no screening for each strategy are provided in the Supporting Information Appendix (Table  A24-A26) . When compared with no screening, all strategies were estimated to be associated with a CER close to or lower than the indicative WTP threshold in Australia of A$50,000/ LYS in all three scenarios. Figure 1 shows the cost-effectiveness planes for Scenarios 1-3. The strategies identified on the cost-effectiveness frontier and the associated ICERs are marked. Given the indicative WTP threshold, only 2-yearly iFOBT (i.e. the fully rolled-out NBCSP) (ICER: A$2,984/LYS-A$5,981/LYS) would be costeffective in all adherence scenarios. The strategy assuming annual screening with iFOBT was also found to be costeffective in Scenarios 2 and 3 (ICER compared to 2-yearly iFOBT: A$14,162/LYS-A$18,798/LYS) but not in Scenario 1 (Fig. 1) . Overall, considering results for all adherence scenarios, the planned program (2-yearly iFOBT screening at 50-74 years) was the most effective strategy for which costeffectiveness was consistently under the WTP threshold. Table 4 shows the estimated number of iFOBTs, pDNA tests, fDNA tests, colonoscopies, sigmoidoscopies and CTCs in the lifetime of 100,000 persons alive at 40 years for each strategy. Strategies that assumed a more frequent screening interval were associated with a higher number of screening tests. In all adherence scenarios, the strategies which were predicted to lead to the highest number of colonoscopy procedures were screening with 10-yearly colonoscopy (35-172% increase in number of colonoscopies compared to 2-yearly iFOBT i.e. the fully rolled-out NBCSP), once-off colonoscopy at 50 years combined with 2-yearly iFOBT (38-86% increase) and annual iFOBT (48-93% increase). Once-lifetime or 10-yearly screening with sigmoidoscopy and 10-yearly CTC screening were estimated to lead to the lowest number of colonoscopies. Figure 2 shows the estimated NNC to prevent one colorectal cancer death for each strategy in comparison to no screening. The "benefit-harms frontier" (i.e. strategies with the optimal balance between benefit and harm compared to strategies with similar effectiveness) and the INNC of the "dominating" strategies are marked (Fig. 2) . Once-off sigmoidoscopy screening, 10-yearly CTC screening (INNC: 27-29 ACs/ CDP), 2-yearly iFOBT screening (INNC: 39-117 ACs/CDP) and annual iFOBT screening (INNC: 61-263 ACs/CDP) were identified on the "benefit-harms frontier" in all scenarios. Once-off sigmoidoscopy screening at 55 years combined with 2-yearly iFOBT screening at 60-74 years (INNC: 31-35 ACs/ CDP) was also identified on the frontier in scenarios assuming realistic screening behaviour (Scenarios 2 and 3). The planned program (2-yearly iFOBT screening) was found to be associated with a favourable benefits-to-harm balance, compared to the other strategies considered in this evaluation. Detailed model estimates of NNC to prevent one colorectal cancer case or one colorectal cancer death compared to 2-yearly iFOBT are provided in the Supporting Information Appendix (Table A27-A29) .
Resource utilisation
Benefit-to-harm ratio
Sensitivity analysis
Detailed outcomes for sensitivity analysis are provided in the Supporting Information Appendix Tables A30-A55. In the sensitivity analysis, which was conducted in the context of assuming 100% adherence, no impact was seen on the main costeffectiveness findings when key parameters were varied across the feasible ranges specified ( Table 2) . As for the base case analysis, in all sensitivity analyses, strategies identified on the costeffectiveness frontier were (in the order of increasing effectiveness) 2-yearly iFOBT screening (the fully rolled-out NBCSP), annual iFOBT screening, and once-off colonoscopy screening at 50 years combined with 2-yearly iFOBT screening. 2-yearly iFOBT screening was the only strategy found to be costeffective in all one-way sensitivity analyses in context of an indicative WTP threshold of A$50,000/LYS in Australia. It was associated with ICER of: A$1,106/LYS-A$7,546/LYS across all sensitivity analyses findings. No other strategies identified on the frontier were found to be cost-effective in the sensitivity analyses for any model runs.
Supplementary analysis
Detailed outcomes for supplementary analysis are provided in the Supporting Information Appendix (Table A56 -A59 and Fig.  A19 ). The estimated colorectal cancer incidence and colorectal cancer mortality age-standardised rates in the supplementary analysis were predicted to be only slightly higher (<1 per 100,000 persons) in all screening strategies and participation scenarios when compared to the base case findings. The relative reduction in colorectal cancer incidence and mortality rates (vs. no screening) and relative rankings of the strategies in terms of cost-effectiveness were very similar to the base case findings.
Discussion
This is the first study that has performed a comprehensive evaluation of the health benefits, harms, and costeffectiveness of the NBCSP Australia-2-yearly iFOBT screening in people aged 50-74 years-in relation to other potential colorectal cancer screening strategies using alternative screening modalities, including pDNA, fDNA, sigmoidoscopy, CTC and colonoscopy. We found that a number of strategies could provide substantial reductions in both colorectal cancer incidence and mortality in a cohort of perfectly adherent people (74% mortality reductions). Of the strategies considered, only biennial iFOBT screening (ICER: A$2,984/LYS-A$5,981/LYS) was consistently cost-effective at different levels of participation, given the indicative WTP threshold in Australia of A$50,000/LYS. A number of strategies were found to be associated with a favourable benefitharm ratio; once-off sigmoidoscopy, 10-yearly CTC screening, and 2-yearly iFOBT screening were consistently found to have a favourable benefit-to-harm balance in all participation scenarios. We also found that the existing NBCSP was one of the most effective, and also a cost-effective, option for bowel cancer screening in Australia. The NBCSP is associated with the one of the most favourable balance of benefits to-harms of all options considered, with 35-49 people needing to undergo colonoscopy for each cancer death prevented compared to no screening.
A strength of our study is that we used a comprehensive and calibrated model of colorectal cancer natural history that incorporated two biological pathways of colorectal cancer development-the adenoma-carcinoma pathway and the serrated pathway. Using this unique platform, we were able to perform a comprehensive evaluation of the health benefits, harms, and cost-effectiveness of various potentially feasible alternatives to the fully rolled-out NBCSP, and we were able to take into account varying levels of adherence. We incorporated colorectal cancer treatment costs that are consistent with the recent estimates in Australia, which has been rapidly increasing in the past two decades. 36 A limitation of the study was that influential parameters including screening test costs, screening participation and screening test performance for alternative modalities to iFOBT were based on assumptions, by necessity. The item costs assumed for potential alternative screening tests were based on the current item cost in Australia (e.g. for colonoscopy) or in other countries (e.g. for novel tests such as fDNA). These costs, however, have the potential to decrease if the test were to be used as a primary screening test within the NBCSP, and thus the costeffectiveness of some of the strategies considered may improve in the future. There were great uncertainties associated with the screening participation rates that could potentially be achieved by using different screening modalities in Australia; however, the impact of these uncertainties was assessed by evaluating the strategies in scenarios assuming different screening adherence. The modelled compliance rate to colonoscopy follow-up after positive iFOBT (71%) was based on the current rate reported in Australia. It is likely to be an underestimate of the actual compliance rate due to underreporting of attendance in the context of nonmandatory reporting of colonoscopy to the NBCSP register. 52 Our assumptions for test characteristics for the different screening modalities were underpinned by different levels of evidence, and in particular our findings for fDNA, pDNA and CTC should be considered exploratory since the test assumptions were based on data from cross-sectional studies only. Finally, quality-adjusted-life-years (QALYs) were not considered in the cost-effectiveness analysis, and thus we could not incorporate the quality of life (as well as survival) benefits experienced due to early detection via screening.
The recent evaluation conducted by the USPSTF compared the burden (i.e. number of colonoscopies) and effectiveness (i.e. life-years gained) of a large number of screening strategies involving HSgFOBT, iFOBT, fDNA, sigmoidoscopy with/without interval HSgFOBT or iFOBT, CTC and colonoscopy in the context of 100% screening adherence for all strategies. 18 Based on the findings, the USPSTF recommended 10-yearly colonoscopy screening, 10-yearly sigmoidoscopy screening combined with annual iFOBT, 5-yearly CTC screening or annual iFOBT screening for people 50-75 years, based on the best balance of benefits to harms, in the U.S. context. 18 For strategies considered in both evaluations, our predictions of reductions in colorectal cancer incidence and mortality rates, and the additional number of colonoscopies per life-years saved were broadly consistent with the findings of the USPSTF evaluation. However, we were able to extend the USPSTF work by relating findings to the operation of a centrally organised population screening program and examining the health outcomes and burden at realistic levels of screening participation. We also extended the work by considering cost-effectiveness. Because we considered this broader range of factors -benefits, harms and costeffectiveness-in our evaluation, our final conclusions about the optimal screening strategies for colorectal cancer screening differ somewhat to the U.S. evaluation. 18 Once-off screening with sigmoidoscopy at 60 years was predicted to reduce the age-standardised colorectal cancer incidence and mortality rates over the lifetime of perfectly adherent cohorts by 35% and 40%, respectively. We also estimated reductions of 48% and 52%, respectively, at 17 years after once-off sigmoidoscopy screening at 60 years, which are broadly consistent with the long-term outcomes of the UK Flexible Sigmoidoscopy Screening Trial, which found a reduction of 35% (HR: 0.65 [95% CI 0.59-0.71]) in colorectal cancer incidence and a reduction of 41% (HR: 0.59 [0.49-0.70]) in colorectal cancer mortality in per protocol individuals who had an once-off screening with sigmoidoscopy at the age between 55 and 64 years, after 17 years of follow-up. 7 We assumed that the cost of CTC would be similar to the current MBS item cost in Australia in the baseline analysis; however, this cost estimate is unlikely to take into account the costs associated with developing the necessary infrastructure that would be required for CTC to be used more widely in screening. We have examined the impact of higher CTC cost (A$720) in the sensitivity analysis; 10-yearly CTC was not found to be cost-effective (dominated by 2-year iFOBT screening, i.e. the planned program) in both the base case analysis and the sensitivity analysis. It should also be noted that our evaluation did not take into account the health services challenges that would be required for the NBCSP to use technology other than iFOBT as the primary screening test.
It should also be noted that all our findings for pDNA and fDNA screening should be considered exploratory, since the performance of these more novel tests, which underpins this modelled evaluation, has not yet been tested in terms of longitudinal outcomes or in randomised controlled trials. In this exploratory analysis, we found that screening with fDNA at 5-yearly intervals at a test cost of A$400-878 (based on current U.S. costs) was not cost-effective, consistent with previous studies findings. 53, 54 Screening with fDNA was also found to be associated with a less favourable benefit-to-harm balance compared to iFOBT screening, consistent with the recent USPSTF evaluation. 18 Our finding that 2-yearly iFOBT screening would be less costly and more effective than 2-yearly plasma DNA screening is also consistent with previous findings. 55, 56 Our results indicate that screening with the plasma DNA test is less effective than iFOBT in preventing colorectal cancer and death due to the lower test sensitivity in detecting the precursors of colorectal cancer. By contrast, offering plasma DNA testing only for under-screened individuals could result in a modest improvement in colorectal incidence and mortality overall. However, this would need to be introduced with very careful controls to avoid potential "leakage" in participation from the main iFOBT program; any leakage from the main program to the add-on program is expected to result in a detrimental effect in the overall effectiveness of the screening program. These aspects require further evaluation before the introduction of plasma DNA testing could be considered.
The Policy1-Bowel platform will in the future be harnessed to consider a range of important policy questions for the NBCSP in Australia, including the possible age-extension of the program (starting at 40 or 45 years, or ceasing screening at 79 or 84 years), the role of other newly emerging screening technologies (or incorporation of new evidence on the effectiveness or costs of the technologies examined here), and the possible role of a risk-based approach to screening, wherein individuals are screened according to their a priori risk of developing colorectal cancer in their lifetime.
Conclusion
There are considerable uncertainties about the long-term program impact of pDNA and fDNA screening because longitudinal data on long-term mortality benefits are not yet available. We modelled the impact of these screening technologies in Australia based on the currently available data. We found that the fully rolled-out NBCSP is one of the most effective options for bowel cancer screening in Australia, and is also cost-effective. The costeffectiveness of the program is high even in the context of the current lower participation rates, and the cost-effectiveness would be sustained if participation could be improved. The benefits of the program would scale with increasing participation. The balance of benefits to harms, represented by the numberneeded-to-colonoscope for each colorectal cancer death prevented, also appears to be favourable for the current NBCSP. An updated long-term impact analyses could be performed when more evidence on longitudinal cancer incidence and mortality outcomes become available for fDNA and pDNA.
